14895-71-7Relevant academic research and scientific papers
ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF)
-
Paragraph 127; 136-137, (2020/09/19)
Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.
Stereoselective synthesis of Certonardolsterol D3
Jiang, Biao,Shi, He-ping,Xu, Min,Wang, Wan-jun,Zhou, Wei-shan
, p. 9738 - 9744 (2008/12/22)
The first stereoselective synthesis of Certonardolsterol D3 was described. Ene reaction and improved allylic oxidation were employed as key steps for efficient construction of the desired 3β,6α,15β-triol steroidal framework. The chiral side cha
